


NEW!

THERAPEUTIC DRUG MONITORING ELISA




-2

This range of ELISA is designed to specifically measure **free and partially bound drug**



-3

This range of ELISA is designed to specifically measure **total drug (free, bound, partially bound)**



-4

This range of ELISA is designed to specifically measure the **bound drug complex**

KRISHGEN IS PROUD TO ANNOUNCE THE LAUNCH OF THE NEW RANGE OF KRIBIOLISA: FAST, SENSITIVE, AND SPECIFIC ASSAYS FOR SPECIFIC DETECTION OF DRUGS WITHIN SAMPLES.

INTRODUCTION

When the mAb and the target both circulate in vivo, various molecular species of mAb and target co-exist in a dynamic equilibrium include: free drug, free circulating target, total drug and the total target.

It has long been acknowledged that data on different drug and target species (e.g., free vs total levels of drug target as two possible biomarkers) may satisfy different needs. Depending on the information required for decision-making, the data required and hence the selection of assay (free, total or both) may differ at each phase of drug development.

Free drug levels reflect the availability of the active drug, while the total or bound drug complex is of importance when checking for efficacy or dynamic interactions of the drug, and for other PK/PD assessments. Thus, it is important to understand the information needed at different stages of drug development.


The new range of specific target ELISA not only quantify the amount of drug in serum, but also help detect, distinguish, and quantify free and bound drug in a sample.

Amongst many benefits of Krishgen ELISA, it is important to note that we use anti-idiotypic antibodies in these assays to ensure a very high degree of specificity.

WHAT ARE ANTI IDIOTYPIC ANTIBODIES?

When one antibody binds to an idiotope of another antibody it is referred to as an anti-idiotypic antibody. The variable part of an antibody including the unique antigen binding site is known as the idiotype. The combination of epitopes within the idiotype (i.e. the idiotopes) is unique for each antibody, see figure 1.

Fig 1. Antibody idiotope - the unique set of antigenic determinants of the variable region of an antibody. Because most therapeutic monoclonal antibodies developed today are human or humanized, the most likely immunogenic epitopes for the induction of anti-drug antibodies (ADA) lie within the hypervariable complementarity determining regions (CDR) that provide the majority of the binding contacts. Anti-idiotypic antibodies can be generated to bind specifically to one monoclonal antibody drug. These highly specialized antibodies can be used to set up pharmacokinetic (PK) assays in different formats to measure free or total drug levels in preclinical and clinical samples, or as positive controls in ADA assays.



ELISA FOR FREE AND PARTIALLY BOUND DRUG

- KBI1018-2 Cetuximab (ERBITUX) ELISA
(measures free and partially bound drug)
- KBI1026-2 Denosumab (PROLIA) ELISA
(measures free and partially bound drug)

ELISA FOR BOUND DRUG COMPLEX

- KBI1015-4 Adalimumab Antigen Capture ELISA
(measures bound drug complex)
- KBI1017-4 Trastuzumab (HERCEPTIN) ELISA
(measures free and partially bound drug)
- KBI1019-4 Golimumab (SIMPONI) ELISA
(measures bound drug complex)
- KBI1021-4 Omalizumab (XOLAIR) ELISA
(measures free and partially bound drug)
- KBI1025-4 Ipilimumab (YERVOY) ELISA
(measures bound drug complex)
- KBI1029-4 Ranibizumab (LUCENTIS) ELISA
(measures bound drug complex)

ELISA FOR TOTAL DRUG COMPLEX (FREE, BOUND, PARTIALLY BOUND)

- KBI1011-3 Infliximab (REMICADE) ELISA
(measures total drug)
- KBI1013-3 Etanercept (ENBREL) ELISA
(measures total drug)
- KBI1019-3 Golimumab (SIMPONI) ELISA
(measures total drug)
- KBI1022-3 Tocilizumab (ACTEMRA) ELISA
(measures total drug)
- KBI1029-3 Ranibizumab (LUCENTIS) ELISA
(measures total drug)

ANTI-TNF ALPHA AND INFLAMMATION BLOCKER MABS

INFLIXIMAB
ETANERCEPT
CERTOLIZUMAB
USTEKINUMAB
NATALIZUMAB
VEDOLIZUMAB

ADALIMUMAB
GOLIMUMAB
VEDOLIZUMAB
TOCILIZUMAB
ALEMTUZUMAB

ANTI-CANCER MABS

BEVACIZUMAB
TRASTUZUMAB
DARATUMUMAB
PANITUMUMAB

RITUXIMAB
CETUXIMAB
OBINUTUZUMAB

IMMUNE CHECKPOINT BLOCKER MABS (PD-1, PD-L1, CTLA4)

ATEZOLIZUMAB
PEMBROLIZUMAB
DURVALUMAB

IPILIMUMAB
NIVOLUMAB
TREMELIMUMAB

OSTEOPOROSIS MABS

DENOSUMAB

ANTI-ALERGEN MABS

OMALIZUMAB

AMD

RANIBIZUMAB

PRODUCT BUNDLING OPPORTUNITIES:

Krishgen TDM ELISA may be of assistance in introducing other Krishgen kits to researchers within the therapeutic fields. Working on biologics and mAbs includes the detecting and often, quantifying of various cytokines and biomarkers that are affected by the drug. Your customer may therefore be interested in purchasing biomarker ELISA kits for related mAbs.

Krishgen manufactures a complete portfolio of specific, sensitive ELISA kits for human and animal cytokine or biomarker studies.

In particular, TNF-Alpha, IL-6, IL-8 and other Interleukins, along with IFN Gamma and immune checkpoints like PD-1, PD-L1 ELISA are often useful in PK / ADA studies.

KRISHGEN BioSystems

OUR REAGENTS. YOUR RESEARCH.